Investigation of the Characteristics of Chronic Pain Developing After COVID-19

Completed

• Conditions: Covid19; Coronavirus; Chronic Pain

• Registration Number: NCT04883216
• Lead Sponsor: Istanbul University

Brief Summary

Data on pain after COVID-19 were generally collected from hospitalized patients and only include information on acute pain conditions. However, the characteristics of the chronic pain experienced after COVID-19 are unknown. For this reason, the treatment and recommendations for patients who present with chronic pain after COVID-19 are not clear. Our goal is to determine the characteristics and risk factors of chronic pain developing in COVID-19 patients and to create specific treatment recommendations for these patient groups with further studies.

Detailed Description

Data on pain developing after COVID-19 were generally collected from hospitalized patients and only include information on acute pain conditions seen after the ilness. It is noteworthy that headache and musculoskeletal pain were seen common in first few weeks. However, the characteristics (mechanical, inflammatory, central sensitization, anxiety-related, etc.) of the chronic pain experienced are unknown. For this reason, the treatment and recommendations for patients who present with chronic pain after COVID-19 are not clear. Our goal is to determine the characteristics and risk factors of chronic pain developing in COVID-19 patients and to create specific treatment recommendations for these patient groups with further studies.

Study Timeline

• Study Start: 2021-03-24
• Study First Submitted: 2021-05-09
• Study First Submitted QC: 2021-05-10
• Study First Posted: 2021-05-12
• Primary Completion: 2021-12-31
• Study Completion: 2021-12-31
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-18
• Last Update Posted: 2022-04-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 776

Inclusion Criteria

1. Being over the age of 18
2. SARS-CoV-2 infection demonstrated with the PCR test (testing date irrelevant)
3. Pain developed or increased after having COVID-19

Exclusion Criteria

1. Mental retardation or mental status not eligible to answer the questionnaires

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Self-Leeds Assessment of Neuropathic Symptoms & Signs (S-LANSS) Pain Score	up to 1 year	The S-LANSS aims to identify pain of predominantly neuropathic origin, as distinct from nociceptive pain, without the need for clinical examination.
The Hospital Anxiety and Depression Scale (HADS) Score	up to 1 year	The Hospital Anxiety and Depression Scale (HADS) is a self-assessment questionnaire that has been found to be a reliable instrument for detecting states of anxiety and depression in the setting of hospital outpatient clinic. The HADS questionnaire has seven items each for depression and anxiety subscales.
Central Sensitization Inventory (CSI)	up to 1 year	The Central Sensitisation Inventory (CSI) is a self-report outcome measure designed to identify patients who have symptoms that may be related to central sensitisation (CS) or central sensitivity syndromes (CSS) such as fibromyalgia, neck injury, temporomandibular joint disorder or migraine/tension headaches. CSI includes 25 questions related to common CSS symptoms.
Visual Analog Scale (VAS) for Pain	up to 1 year	The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain."
Self-report Demographic Questionnaire	up to 1 year	A questionnaire made by the researchers to understand the demographic characteristics of the patients included.

Trial Locations

Locations (1)

Istanbul University Istanbul Faculty of Medicine; 🇹🇷 İstanbul, Turkey